Cargando…
Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment
People with cardiovascular disease (CVD) often contract coronavirus disease 2019 (COVID‐19). However, the interaction between COVID‐19 and CVD is unclear. In this systematic review, the available evidence for the crosstalk between COVID‐19 and CVD and its treatment was analysed. A search was perform...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754975/ https://www.ncbi.nlm.nih.gov/pubmed/32935928 http://dx.doi.org/10.1002/ehf2.12960 |
_version_ | 1783626284949045248 |
---|---|
author | Ye, Qing Lu, Dezhao Shang, Shiqiang Fu, Junfen Gong, Fangqi Shu, Qiang Mao, Jianhua |
author_facet | Ye, Qing Lu, Dezhao Shang, Shiqiang Fu, Junfen Gong, Fangqi Shu, Qiang Mao, Jianhua |
author_sort | Ye, Qing |
collection | PubMed |
description | People with cardiovascular disease (CVD) often contract coronavirus disease 2019 (COVID‐19). However, the interaction between COVID‐19 and CVD is unclear. In this systematic review, the available evidence for the crosstalk between COVID‐19 and CVD and its treatment was analysed. A search was performed in the electronic databases MEDLINE and EMBASE. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infects human cells via angiotensin‐converting enzyme 2. SARS‐CoV‐2 can cause CVD by inducing cytokine storms, creating an imbalance in the oxygen supply and demand and disrupting the renin–angiotensin–aldosterone system; SARS‐CoV‐2 infection can also lead to the development of CVD through the side effects of therapeutic drugs, psychological factors, and aggravation of underlying CVD. The most common CVDs caused by SARS‐CoV‐2 infection are acute myocardial injury, arrhythmia, and heart failure. Studies have found that there is an interaction between COVID‐19 and CVD. Underlying CVD is associated with a high risk of mortality in patients with COVID‐19. SARS‐CoV‐2 infection can also cause new‐onset CVD. Clinicians need to pay close attention to cardiovascular complications during the diagnosis and treatment of patients with COVID‐19 to reduce patient mortality. |
format | Online Article Text |
id | pubmed-7754975 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77549752020-12-23 Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment Ye, Qing Lu, Dezhao Shang, Shiqiang Fu, Junfen Gong, Fangqi Shu, Qiang Mao, Jianhua ESC Heart Fail Reviews People with cardiovascular disease (CVD) often contract coronavirus disease 2019 (COVID‐19). However, the interaction between COVID‐19 and CVD is unclear. In this systematic review, the available evidence for the crosstalk between COVID‐19 and CVD and its treatment was analysed. A search was performed in the electronic databases MEDLINE and EMBASE. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infects human cells via angiotensin‐converting enzyme 2. SARS‐CoV‐2 can cause CVD by inducing cytokine storms, creating an imbalance in the oxygen supply and demand and disrupting the renin–angiotensin–aldosterone system; SARS‐CoV‐2 infection can also lead to the development of CVD through the side effects of therapeutic drugs, psychological factors, and aggravation of underlying CVD. The most common CVDs caused by SARS‐CoV‐2 infection are acute myocardial injury, arrhythmia, and heart failure. Studies have found that there is an interaction between COVID‐19 and CVD. Underlying CVD is associated with a high risk of mortality in patients with COVID‐19. SARS‐CoV‐2 infection can also cause new‐onset CVD. Clinicians need to pay close attention to cardiovascular complications during the diagnosis and treatment of patients with COVID‐19 to reduce patient mortality. John Wiley and Sons Inc. 2020-09-16 /pmc/articles/PMC7754975/ /pubmed/32935928 http://dx.doi.org/10.1002/ehf2.12960 Text en © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Reviews Ye, Qing Lu, Dezhao Shang, Shiqiang Fu, Junfen Gong, Fangqi Shu, Qiang Mao, Jianhua Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment |
title | Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment |
title_full | Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment |
title_fullStr | Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment |
title_full_unstemmed | Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment |
title_short | Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment |
title_sort | crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754975/ https://www.ncbi.nlm.nih.gov/pubmed/32935928 http://dx.doi.org/10.1002/ehf2.12960 |
work_keys_str_mv | AT yeqing crosstalkbetweencoronavirusdisease2019andcardiovasculardiseaseanditstreatment AT ludezhao crosstalkbetweencoronavirusdisease2019andcardiovasculardiseaseanditstreatment AT shangshiqiang crosstalkbetweencoronavirusdisease2019andcardiovasculardiseaseanditstreatment AT fujunfen crosstalkbetweencoronavirusdisease2019andcardiovasculardiseaseanditstreatment AT gongfangqi crosstalkbetweencoronavirusdisease2019andcardiovasculardiseaseanditstreatment AT shuqiang crosstalkbetweencoronavirusdisease2019andcardiovasculardiseaseanditstreatment AT maojianhua crosstalkbetweencoronavirusdisease2019andcardiovasculardiseaseanditstreatment |